Daily Trades
- Dylan Jovine
I recommend selling shares of Immunogen (SYM: IMGN) here at $29.89.
- Dylan Jovine
For our December issue, I’m adding a stock to our weight-loss trade: Altimmune (SYM: ALT) here at $3.75.
- Dylan Jovine
Shares of one of Immunogen (SYM: IMGN) are set to open up 94% after AbbVie agreed to buy the company for $31.26.
- Dylan Jovine
Exciting news on core holding Immunogen (SYM: IMGN) this week.
- Dylan Jovine
The company has strong technology…made even stronger by the fact that NVIDIA invested $50 million in them this past July
- Dylan Jovine
Let's start by closing out one of our older positions for a small profit.
- Dylan Jovine
ImmunoGen Inc. (SYM:IMGN) added 17% pre-market this morning to $16.50, a 211% gain from our recommended price of $5.30.
- Dylan Jovine
Shares of one of ImmunoGen (SYM: IMGN) are up 100% today after the company posted great Phase 3 trial results for its ovarian cancer drug, Elahere.
- Dylan Jovine
An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population).
As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.
- Dylan Jovine
For 40 years, ImmunoGen has been targeting a better life for people with cancer, as they believe it’s not enough to disrupt the progress of the disease, they want to keep cancer from disrupting someone's life.
deal of the month
Categories
Insiders Are Selling! What Record-Low Insider Buying Signals for the Stock Market
Can Hurricane Season Create a Debt Crisis??
Hurricane Season & US Debt Crisis: Why Rising Insurance Costs Signal Bigger Problems
Recent posts
Tags
Connect with Us
- Dylan Jovine
I recommend selling shares of Immunogen (SYM: IMGN) here at $29.89.
- Dylan Jovine
For our December issue, I’m adding a stock to our weight-loss trade: Altimmune (SYM: ALT) here at $3.75.
- Dylan Jovine
Shares of one of Immunogen (SYM: IMGN) are set to open up 94% after AbbVie agreed to buy the company for $31.26.
- Dylan Jovine
Exciting news on core holding Immunogen (SYM: IMGN) this week.
- Dylan Jovine
The company has strong technology…made even stronger by the fact that NVIDIA invested $50 million in them this past July
- Dylan Jovine
Let's start by closing out one of our older positions for a small profit.
- Dylan Jovine
ImmunoGen Inc. (SYM:IMGN) added 17% pre-market this morning to $16.50, a 211% gain from our recommended price of $5.30.
- Dylan Jovine
Shares of one of ImmunoGen (SYM: IMGN) are up 100% today after the company posted great Phase 3 trial results for its ovarian cancer drug, Elahere.
- Dylan Jovine
An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population).
As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.
- Dylan Jovine
For 40 years, ImmunoGen has been targeting a better life for people with cancer, as they believe it’s not enough to disrupt the progress of the disease, they want to keep cancer from disrupting someone's life.
Get FREE Daily Stock Tips
Join and receive market insider stock picks, trade alerts and unique investing insights
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.
